FDA Regulation and the Dynamic Nature of AI - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Regulatory Frameworks for AI and Their Evolving Landscape

  • By

  • kffconnorg

  • September 15, 2026

Share

Objective:

To explore how the FDA's regulatory framework for medical devices applies to the evolving capabilities of AI in healthcare.

Approach:
  • Discussion: Chip Kahn hosts a discussion with Dr. Brian Miller on the implications of AI regulation in healthcare.
Key Findings:
  • The FDA's 1976 framework for medical devices is being examined for its applicability to AI.
  • Dr. Miller expresses concern that fear-driven regulation could hinder the potential benefits of AI in healthcare.
  • The FDA is seeking stakeholder feedback on potential regulatory approaches for AI.
  • The discussion was recorded shortly before the FDA issued a discussion paper describing potential regulatory approaches.
Interpretation:

Dr. Miller suggests that the current manual medical system is less safe and consistent than perceived, and he warns that regulation driven by fear could limit the opportunities AI presents.

Limitations:
  • The discussion reflects the perspectives of the host and guest, which may not encompass all viewpoints on AI regulation.
Conclusion:

The episode emphasizes the need for regulation that balances safety and innovation in AI healthcare applications.

Sources:

Original Source(s)

FDA Regulation and the Dynamic Nature of AI

  • by kffconnorg

  • September 15, 2026

Related Content

AI-Designed Binder Improves CAR T Cell Activity in Mice

Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control

  • September 15, 2026

  • 3 min
Half of pediatric mental health visits hit smaller EDs

Pediatric suicide-related visits showed a similar distribution, while patient and diagnostic characteristics differed across emergency settings.

Musings from The Power List: Dajun Yang

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

  • September 15, 2026

  • 5 min